Literature DB >> 19027990

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.

Yasuo Kubota1, Kozo Yoneda, Kozo Nakai, Junko Katsuura, Tetsuya Moriue, Yoshie Matsuoka, Izumi Miyamoto, Yukihiro Ohya.   

Abstract

BACKGROUND: The efficacy of combination therapy with topical corticosteroids and tacrolimus in the treatment of atopic dermatitis remains to be established.
OBJECTIVE: Our aim was to determine whether a regimen of sequential application of topical corticosteroids and topical tacrolimus is effective in the treatment of pediatric atopic dermatitis. A second goal was to assess the impact of this treatment regimen on quality of life (QOL) and the response shift on QOL changes.
METHODS: The study regimen consisted of 3 phases. In the induction phase, patients were treated for a 2-week period with application of 0.03% tacrolimus ointment in the morning and application of a strong- or weak-potency corticosteroid ointment in the evening. In the transitional phase, they were treated for an additional 2 weeks with 0.03% tacrolimus ointment twice daily on weekdays and concurrent application of tacrolimus and a topical corticosteroid ointment on weekend days. In the maintenance phase, the corticosteroid ointment was discontinued and 0.03% tacrolimus ointment was applied twice daily for an additional 2 weeks. Daily application of tacrolimus ointment was then discontinued and replaced by an emollient with application of 0.03% tacrolimus ointment only when necessary for an additional 6 weeks. The Eczema Area and Severity Index score, Investigators' Global Assessment, severity of pruritus and sleep disturbance scores, and QOL evaluation were measured. After 12 weeks, the patients completed a retrospective version of the pretreatment QOL evaluation for analysis of response shift bias.
RESULTS: Eczema Area and Severity Index scores decreased by the sixth week, and continued improvement was observed during an additional 6-week period. Both the pruritus and sleep disturbance scores decreased throughout the study. Of patients, 90% showed marked clinical improvement at week 6 and 96% at week 12. On the Children's Dermatology Life Quality Index and the Infant's Dermatology QOL Index survey, mean QOL scores improved after completion of therapy at week 12. The mean difference between the pretest and the retrospective pretest scores indicated the presence of a response shift bias. LIMITATIONS: This was an uncontrolled, open-label study. Conclusions are limited by the small sample size.
CONCLUSIONS: A fixed sequential regimen of application of tacrolimus ointment with tapering of topical corticosteroids may limit the long-term use and adverse effects of topical corticosteroids, while maintaining clinical control of pediatric atopic dermatitis and improving the QOL. The finding of a response shift bias suggests that parents/guardians underestimate the seriousness of skin disease and its impact on QOL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027990     DOI: 10.1016/j.jaad.2008.09.034

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

1.  Guidelines for improving the stringency of response shift research using the thentest.

Authors:  Carolyn E Schwartz; Mirjam A G Sprangers
Journal:  Qual Life Res       Date:  2010-01-19       Impact factor: 4.147

2.  [Evaluation of quality of life of children with atopic dermatitis before and after treatment].

Authors:  Ying Cheng; Zhen Zhang; Xiao-Yi Liu; Huan He; Ji Chen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-06

3.  Update on the management of chronic eczema: new approaches and emerging treatment options.

Authors:  Hobart W Walling; Brian L Swick
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-07-28

4.  Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment.

Authors:  Jung Eun Kim; Hyun Jeong Kim; Bark-Lynn Lew; Kyung Ho Lee; Seung Phil Hong; Yong Hyun Jang; Kui Young Park; Seong Jun Seo; Jung Min Bae; Eung Ho Choi; Ki Beom Suhr; Seung Chul Lee; Hyun Chang Ko; Young Lip Park; Sang Wook Son; Young Jun Seo; Yang Won Lee; Sang Hyun Cho; Chun Wook Park; Joo Young Roh
Journal:  Ann Dermatol       Date:  2015-10-02       Impact factor: 1.444

Review 5.  A Systematic Scoping Literature Review of Publications Supporting Treatment Guidelines for Pediatric Atopic Dermatitis in Contrast to Clinical Practice Patterns.

Authors:  Elaine C Siegfried; Jennifer C Jaworski; Paola Mina-Osorio
Journal:  Dermatol Ther (Heidelb)       Date:  2018-06-01

Review 6.  Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits.

Authors:  Mamitaro Ohtsuki; Hiroshi Morimoto; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2018-06-21       Impact factor: 4.005

7.  Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review.

Authors:  Sanjay Singh; Baldeep Kaur Mann
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-06-22

Review 8.  Interventions to Increase Treatment Adherence in Pediatric Atopic Dermatitis: A Systematic Review.

Authors:  Alexandria M Bass; Kathryn L Anderson; Steven R Feldman
Journal:  J Clin Med       Date:  2015-01-27       Impact factor: 4.241

Review 9.  Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.

Authors:  Elaine C Siegfried; Jennifer C Jaworski; Jennifer D Kaiser; Adelaide A Hebert
Journal:  BMC Pediatr       Date:  2016-06-07       Impact factor: 2.125

10.  PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis.

Authors:  Linda Stein Gold; Javier Alonso-Llamazares; Jean-Philippe Lacour; Richard B Warren; Stephen K Tyring; Leon Kircik; Paul Yamauchi; Mark Lebwohl
Journal:  Adv Ther       Date:  2020-09-23       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.